. 86Y mutant frequency (where available -see Methods) and prevalence after introduction of ACT policy in locations which measured mutant prevalence at least twice, at least 3 years apart after the introduction of ACT policy, and with at least one non-zero observation. Panel outline colours indicate which ACT was first-line. Burkina Faso BD = Bobo-Dioulasso. Figure S3 . 184F mutant frequency (where available -see Methods) and prevalence after introduction of ACT policy in locations which measured mutant prevalence at least twice, at least 3 years apart after the introduction of ACT policy, and with at least one non-zero observation. Panel outline colours indicate which ACT was first-line. Figure S4 . 1246Y mutant frequency (where available -see Methods) and prevalence after introduction of ACT policy in locations which measured mutant prevalence at least twice, at least 3 years apart after the introduction of ACT policy, and with at least one non-zero observation. Panel outline colours indicate which ACT was first-line. Figure S5 . Rates of change of the prevalence and frequency of the 86Y mutant after introduction of ACT policy. Y axis = log(mutant/wild type prevalence) and log(mutant/wild type frequency) where available in locations which measured mutant prevalence/frequency at least twice, at least 3 years apart after the introduction of ACT policy, and with at least one non-zero observation. The slope gives the selection coefficient in each area. Where possible we fitted a slope for both frequencybased and prevalence-based measures (n=20 locations, shown here), but found this made little difference to the slope in almost all locations. Box outline colours indicate which ACT was first-line. Figure S6 . Rates of change of the 184F mutant after introduction of ACT policy (legend as Figure S5 ). Figure S7 . Rates of change of the 1246Y mutant after introduction of ACT policy (as Figure S5 ).
Figure S8 National first-line ACT policies in countries which also had published Pfmdr1 data, with smaller countries/islands and their policies labelled. Predominant first-line policies were defined for each country as a policy in use for at least 5 years and lasting longer than any other ACT policy in the country. Countries coloured white are areas in which the systematic review did not identify any published Pfmdr1 data, or which had a policy other than AL, AS-AQ or both AL and AS-AQ. Figure S9 . Associations between starting frequency/prevalence of each Pfmdr1 mutation in a location, and its subsequent rate of change in frequency/prevalence (selection coefficient) (see Figures S2-S7 for the individual location data). All mutations show a significantly more negative change in frequency/prevalence as the starting frequency increases (p values indicated are from multilevel model analysis testing for interaction between the starting frequency of each mutation and change in frequency over time -see Methods). Figure S10 . Trends in the 86Y mutation pre-ACT policy (year 0 = year ACT policy introduced). Figure S11 . Trends in the 184F mutation pre-ACT policy (year 0 = year ACT policy introduced). Figure S12 . Trends in the 1246Y mutation pre-ACT policy (year 0 = year ACT policy introduced). Figure S13 . Frequencies of Pfmdr1 haplotypes over time, in locations with more than one survey. The country and location are indicated in the title of each panel, followed by the main ACT policy eventually recommended (though ACT policy was not necessarily in place for the whole of the time series). Year is on the x axis, and total number of samples with haplotypes detected per survey shown above each bar. Table S1 . Associations between rate of selection of mutations Pfmdr1 86Y, 184F, 1246Y in different locations and drug policies, drug consumption and other covariates. Associations were analysed using multi-level regression, allowing for random intercepts and random slopes by location. Regression results give the difference in selection coefficients at different covariate values, assuming 3 parasite generations per year (see methods). Two multivariate models were run separately to estimate the adjusted association between (1) ACT policy and selection and (2) between AL consumption and selection. d mean % febrile RDT+ under five year olds receiving ACT in countries with AL policies during the time period over which Pfmdr1 data were available (estimates from Malaria Atlas Project). Analysed in countries with AL policies only, in a separate model. e After adjusting for chloroquine coverage, transmission intensity and initial mutant frequency (adjusted coefficients are not shown for the other variables).
